3613 results about "Drug delivery" patented technology

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention discloses an optimization analysis system for simulating an anesthesia process, relates to the technical field of anesthesia simulation optimization analysis, and is used for solving the problem of inaccurate anesthesia individualized simulation decision. By constructing an anesthesia simulation system fusing a pharmacokinetic and pharmacodynamic model and a physiological coupling model, dynamic process simulation under individual physiological states and operative characteristics is realized, state evolution trajectories of an induction period, a maintenance period and a resuscitation period can be accurately deduced, and by introducing deep learning calculation and stage continuity constraints, the accuracy of the state evolution trajectories of the induction period, the maintenance period and the resuscitation period is improved. The method comprises the following steps of: establishing a multi-path drug delivery and ventilation strategy, setting a risk-efficiency scoring function, completing state tracking and index evaluation of the whole process, generating a strategy scoring set with confidence information, further supporting an abnormal probability judgment and risk triggering mechanism by the system, and outputting key monitoring parameters and coping strategies, so as to improve the simulation accuracy and stability; therefore, closed-loop control of strategy optimization and risk early warning is realized, and the credibility of the anaesthesia simulation process is improved.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention relates to a painless gastrointestinal endoscope self-adaptive drug delivery method and system based on multi-source physiological signal fusion, and belongs to the technical field of medical artificial intelligence and automatic control. An artificial intelligence model is utilized to deeply extract features and quantitatively evaluate the sedation-analgesia level of a patient, a pharmacokinetics-pharmacodynamics model constructed by a big data platform is utilized to dynamically predict the drug effect according to the individual features and real-time state of the patient, and the anesthetic infusion rate is automatically and accurately adjusted through a closed-loop control algorithm, so that the patient can be accurately infused. Personalization and self-adaption of drug delivery are achieved, an independent safety monitoring mechanism is set, and real-time intervention is conducted on risk events such as respiratory depression. The problems that traditional anesthesia depends on artificial experience, single parameter monitoring is not comprehensive and individualized dynamic adjustment is lacked can be effectively solved, and the safety, comfort and medical efficiency of painless gastrointestinal endoscopy are remarkably improved.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A drug delivery device may include a housing having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include a guard moveably positioned adjacent to the opening and a plunger having a generally cylindrical body portion extending along a longitudinal axis of the container and at least one flange extending radially outwardly from the body portion, wherein the plunger is moveable toward the distal end of the container to expel a drug through the delivery member. The device may further include a plunger biasing member configured to urge the plunger toward the distal end of the container and a releaser member defining a guide configured to receive the at least one flange and an indicator configured to generate an audible signal indicating an end of drug delivery.

The invention discloses a sewage treatment drug delivery control method based on reinforcement learning and particle swarm optimization, and the method achieves the precise control of turbidity and the optimization of drug cost through the dynamic adjustment of particle swarm parameters and the fusion of a reinforcement learning strategy. According to the technical scheme, the method comprises the following steps: combining a PSO algorithm with a DDPG algorithm to construct a drug control model; designing a reward function; the empirical data with the state coverage rate higher than a first preset threshold value are stored in a full-reservation empirical pool, the empirical data with the current policy access larger than a second preset threshold value are reserved in a first-in first-out mode through a policy empirical pool, and mixed sampling is carried out according to a preset proportion; training a drug control model; and inputting the current turbidity value, the drug delivery amount of the last time step, the water inlet flow, the parameters of the water quality detection camera and the future turbidity value into a trained drug control model, and outputting the current drug delivery amount. Through prediction-control closed-loop integration, a raw water turbidity prediction result is fed back to the optimizer, and the method is suitable for real-time adaptive control of a sewage treatment system.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The application relates to a lock ring for a medicament delivery device. The lock ring comprises a hollow main body formed from a plurality of circumferentially extending portions. Each portion is defined between tool split lines defining circumferential ends of the portions. Each circumferential end of a portion is connected to an adjacent portion along a tool split line. The main body comprises a plurality of bearing elements configured to contact a body of a medicament delivery device. Each of the plurality of bearing elements is configured to form a low friction rotation interface. At least one of the plurality of bearing elements is formed proximate to one of the circumferential ends of a portion of the main body.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention discloses a hydrogel patch for gastric perforation repair and a preparation method thereof, and belongs to the technical field of biomedical materials. The preparation method comprises the following steps: dissolving acryloyl valine, acrylic acid, methylene bisacrylamide, a compound A and a photoinitiator in an alcohol solvent, and defoaming to obtain a precursor solution; and placing the precursor solution in a mold, carrying out ultraviolet-induced curing, soaking the obtained hydrogel in a hydrochloric acid solution, and replacing the alcohol solvent to obtain the hydrogel patch for gastric perforation repair. The hydrogel patch provided by the invention has the advantages of strong acid corrosion resistance, good biocompatibility, low swelling ratio, stable adhesion performance in a fluctuating pH environment and the like. The tough and stable adhesion performance ensures that the hydrogel can be permanently and reliably adhered to a gastric perforation part in a dynamic gastric acid environment, and a stable platform is provided for drug delivery, so that the surgical operation time is expected to be shortened, and wound healing is promoted.

Systems and methods can involve wedge dissectors attached to strips in turn attached to medical balloons, for forming serrations within vascular wall tissue for angioplasty as well as drug delivery.

The invention discloses a multi-source data-based medical temperature-adjusting atomization drug delivery system for the pneumology department, relates to the technical field of medical temperature-adjusting atomization drug delivery, and aims to solve the problems that the atomization effect is poor and the atomization process is not intelligent. By adjusting atomization power in different respiratory cycle stages, monitoring airway abnormity and respiratory fluctuation in real time to correct parameters and adapting temperature control and atomization components as required, medicine waste and airway stimulation can be reduced, variables such as air source fluctuation and liquid medicine viscosity can be coped, atomization stability is guaranteed, administration efficiency and safety are improved, and the method is suitable for large-scale popularization and application. The requirements of patients with weak respiratory functions are met, the basic information unit is linked with the medical history of the patients and the medicine information to determine the safe temperature, the atomization rhythm is matched in combination with the respiratory parameters, temperature deviation caused by information dispersion can be avoided, manual errors are reduced, and the medication safety is improved.

Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to lipid nanoparticles for use as drug delivery agents. The lipid nanoparticles are composed of lipopeptide conjugates, where a peptide is bonded to a lipid. The lipid nanoparticles described herein represent a new approach in drug delivery, addressing critical challenges in balancing biodegradability, biocompatibility, and organspecific targeting. The lipid nanoparticles can selectively target and deliver bioactive agents to specific tissues in a subject by modifying specific amino acids and ratios thereof in the peptide of the lipopeptide conjugate.

The present disclosure relates generally to antimicrobial gels. In particular, the present disclosure relates to an antimicrobial gel comprising a eutectic solvent and a gelling agent which can be used as a drug delivery vehicle for antimicrobial agents, including for the topical delivery of antimicrobial agents to the skin of a subject. The present disclosure also relates to processes for preparing the antimicrobial gel, and to methods, uses and compositions comprising the antimicrobial gel.

The present application relates to a sustained release delivery composition of a vesicular monoamine transporter type 2 (VMAT2) inhibitor, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of hyperkinetic movement disorders including, but not limited to, tardive dyskinesia (TD), Huntington's disease (HD) chorea, tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. The present application also relates to a sustained release delivery composition of an antipsychotic agent, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of schizophrenia, bipolar disorder, and other psychiatric diseases or disorders. The method of making or using the composition is also disclosed.

A novel embodiment of a pump system, for example, of the type that would be used in a wearable drug delivery system, comprises dual linear-actuated plungers disposed in a pump chamber. The plungers are coupled to a leadscrew having both left-hand and right-hand threads such that rotation of leadscrew in a first direction moves the plungers together and rotation of leadscrew in a second, opposite direction moves the plungers apart. Movement of the plungers away from each other draws one or more doses of a liquid drug from a reservoir into the pump chamber, while movement of the plungers together forces liquid drug to a patient interface for delivery to the patient.

The disclosure relates to an audible indicator in combination with a drug delivery device having a resilient force member capable of resting in either of two states. In a biased state, the resilient force member is biased and stores energy and in a relaxed state, the resilient force member is relaxed. The resilient force member releases the stored energy when changing from the biased state into the relaxed state, thereby generating an audible signal, wherein the resilient force member is supported by a retaining element in the biased state in order to prevent transition into the relaxed state.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A soaking device and methods of using are used to cool and / or to heat a face of a person for a purpose of inducing a desired and / or intended outcome in that person. The cooling and / or the heating of the face may be sufficient to induce the desired and / or the intended outcome in that person. The desired and / or intended outcome may relate to: release of at least one type of neurotransmitter; trigeminal nerve stimulation; (indirect) vagus nerve stimulation; transdermal drug delivery; bypass of the blood-brain-barrier (BBB); aesthetic medicine; cardiovascular; dermatological; ears, nose, and throat (otolaryngological); ophthalmological; neurological; psychological; endocrinological; and / or rheumatological benefits to that person. At least one step of the method may include receiving at least some of the face within an immersion-liquid for at least a minimum amount of time while the immersion-liquid is within a temperature-range and while the immersion-liquid is within the soaking device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention provides a sustained-release microneedle for treating ill-conditioned pregnancy and a preparation method and application thereof, and relates to the technical field of biological medicines.The sustained-release microneedle for treating ill-conditioned pregnancy comprises a base and a needle tip on the base, the needle tip part of the gel microneedle is made of heparin medicine, and the needle tip part of the gel microneedle is made of gelatin. The heparin medicine comprises heparin, heparin sodium, low-molecular heparin, low-molecular heparin sodium or low-molecular heparin calcium; the needle point part comprises a heparin photo-crosslinking monomer, and the base comprises a biocompatible polymer matrix. The sustained-release microneedle for treating pathological pregnancy provided by the embodiment of the invention has good mechanical strength, skin permeability and anticoagulant activity, can reduce skin bruises caused by subcutaneous injection of heparin, improves abortion caused by infection and inflammation and abortion caused by APS (anti-phospholipid antibody syndrome), can realize sustained release of drugs and increase of drug loading capacity, and has good application prospects. Sustainable drug delivery is achieved, and frequent injection is avoided.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.